BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36347854)

  • 1. Deep learning-based image analysis predicts PD-L1 status from H&E-stained histopathology images in breast cancer.
    Shamai G; Livne A; Polónia A; Sabo E; Cretu A; Bar-Sela G; Kimmel R
    Nat Commun; 2022 Nov; 13(1):6753. PubMed ID: 36347854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
    Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
    van Eekelen L; Spronck J; Looijen-Salamon M; Vos S; Munari E; Girolami I; Eccher A; Acs B; Boyaci C; de Souza GS; Demirel-Andishmand M; Meesters LD; Zegers D; van der Woude L; Theelen W; van den Heuvel M; Grünberg K; van Ginneken B; van der Laak J; Ciompi F
    Sci Rep; 2024 Mar; 14(1):7136. PubMed ID: 38531958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
    J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
    Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
    Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.
    Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W
    Front Immunol; 2022; 13():828560. PubMed ID: 35464416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images.
    Sha L; Osinski BL; Ho IY; Tan TL; Willis C; Weiss H; Beaubier N; Mahon BM; Taxter TJ; Yip SSF
    J Pathol Inform; 2019; 10():24. PubMed ID: 31523482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep learning-based methods for classification of microsatellite instability in endometrial cancer from HE-stained pathological images.
    Zhang Y; Chen S; Wang Y; Li J; Xu K; Chen J; Zhao J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8877-8888. PubMed ID: 37150803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
    Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
    Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods.
    Lloyd IE; Zhou W; Witt BL; Chadwick BE
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):107-113. PubMed ID: 29084060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
    Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
    Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
    Kim HN; Jang J; Heo YJ; Kim B; Jung H; Jang Y; Kang SY; Kim ST; Lee J; Kang WK; Kim KM
    Virchows Arch; 2020 Feb; 476(2):243-250. PubMed ID: 31463730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer.
    Li C; Ma RZ; Han GY; Guo YH; Zhang YN; Zhang YT; Wang H; Zhang YP; Chen FM; Zhang SG; Wang MC; Hao FR; Zhang YX
    Oncol Res Treat; 2020; 43(11):573-583. PubMed ID: 32957100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.